JPMorgan Chase & Co. trimmed its position in Indivior PLC (NASDAQ:INDV - Free Report) by 85.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,790 shares of the company's stock after selling 376,955 shares during the period. JPMorgan Chase & Co.'s holdings in Indivior were worth $805,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Indivior during the fourth quarter valued at approximately $56,000. Stifel Financial Corp acquired a new position in Indivior in the 3rd quarter valued at $100,000. Jane Street Group LLC purchased a new position in shares of Indivior during the 3rd quarter worth $180,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Indivior during the 4th quarter worth $359,000. Finally, Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Indivior during the fourth quarter worth $1,192,000. 60.33% of the stock is owned by institutional investors and hedge funds.
Indivior Price Performance
NASDAQ INDV traded down $0.24 during mid-day trading on Wednesday, hitting $11.51. The company's stock had a trading volume of 748,537 shares, compared to its average volume of 976,951. The stock's fifty day simple moving average is $9.55 and its two-hundred day simple moving average is $10.38. Indivior PLC has a 52-week low of $7.33 and a 52-week high of $18.59. The firm has a market capitalization of $1.59 billion, a P/E ratio of -32.89 and a beta of 0.93.
Indivior (NASDAQ:INDV - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.22 by $0.19. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The company had revenue of $266.00 million for the quarter, compared to analyst estimates of $240.13 million. On average, equities analysts forecast that Indivior PLC will post 1.22 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research firms recently commented on INDV. Piper Sandler dropped their target price on Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research note on Thursday, March 6th. RODMAN&RENSHAW raised shares of Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw started coverage on shares of Indivior in a research note on Tuesday, January 28th. They set a "buy" rating and a $16.00 price target on the stock.
Get Our Latest Stock Analysis on Indivior
About Indivior
(
Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Read More
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
